Zacks Research Expects Increased Earnings for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN) – Research analysts at Zacks Research increased their Q2 2026 EPS estimates for AstraZeneca in a report issued on Thursday, September 11th. Zacks Research analyst Team now anticipates that the company will earn $1.23 per share for the quarter, up from their prior estimate of $1.22. The consensus estimate for AstraZeneca’s current full-year earnings is $4.51 per share. Zacks Research also issued estimates for AstraZeneca’s FY2026 earnings at $5.03 EPS, Q1 2027 earnings at $1.28 EPS, Q2 2027 earnings at $1.39 EPS and FY2027 earnings at $5.70 EPS.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, July 29th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. The firm had revenue of $14.46 billion during the quarter, compared to analysts’ expectations of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business’s revenue for the quarter was up 16.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.24 earnings per share.

Separately, Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a report on Wednesday, July 9th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Stock Down 1.9%

AZN stock opened at $79.56 on Friday. The firm has a 50-day moving average price of $75.95 and a 200-day moving average price of $72.97. The stock has a market capitalization of $246.74 billion, a P/E ratio of 29.91, a price-to-earnings-growth ratio of 1.49 and a beta of 0.37. AstraZeneca has a 12 month low of $61.24 and a 12 month high of $82.41. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

Hedge Funds Weigh In On AstraZeneca

Several hedge funds have recently made changes to their positions in the stock. NewSquare Capital LLC lifted its holdings in shares of AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after buying an additional 218 shares in the last quarter. Confluence Investment Management LLC purchased a new position in shares of AstraZeneca in the first quarter worth $27,000. Larson Financial Group LLC raised its position in AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock valued at $28,000 after purchasing an additional 289 shares during the last quarter. Richardson Financial Services Inc. raised its position in AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after purchasing an additional 149 shares during the last quarter. Finally, FNY Investment Advisers LLC bought a new position in AstraZeneca during the 1st quarter valued at approximately $29,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were given a dividend of $0.505 per share. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s dividend payout ratio is presently 37.97%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.